Equity Profile

ZLAB

Zai Lab Limited

Health CareBiotechnology$2.2B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:00 AM EDT

Zai Lab Limited Misses on Revenue, Stock Down 5.93%

Metric	Actual	Expected	Surprise
EPS	$-0.46	N/A	+20.69%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

Zai Lab Limited Misses on Revenue, Stock Down 5.93%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.46	N/A	+20.69%
Revenue	N/A	N/A	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Zai Lab reported a narrower-than-expected loss per share, which was a positive surprise. However, the stock dropped by nearly 6%, indicating that investors may have been disappointed by the lack of revenue information and guidance. The absence of management commentary could also contribute to uncertainty about the company's future performance.

Company Snapshot

Zai Lab Limited is a biotechnology company focused on developing innovative medicines to address unmet medical needs. Operating in the healthcare sector, Zai Lab is particularly relevant as it seeks to bring new therapies to market in areas like oncology and autoimmune diseases, which are critical in today's healthcare landscape.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and support future investments.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+0.83%

Avg Stock Reaction

-3.30%

Last Quarter Recap

In the last quarter, Zai Lab reported an EPS of -$0.46, slightly missing analyst expectations. The stock reacted positively, gaining 1.55% the following day, indicating some investor optimism despite the loss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Zai Lab's earnings report, especially given the company's recent performance. However, the lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Zai Lab can demonstrate better-than-expected progress in its clinical trials or report a narrower EPS loss, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company reports a larger-than-expected loss or delays in its drug development timelines, it could lead to a negative reaction from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Zai Lab's clinical trials?

Updates on clinical trials can significantly impact the company's future prospects and investor sentiment.

How does Zai Lab plan to manage its operating expenses moving forward?

Understanding expense management is crucial for assessing the company's path to profitability and financial stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of Zai Lab's ongoing clinical trials, which could yield positive results sooner than anticipated.

Supporting Evidence

The options market is pricing a significant move, indicating expectations of volatility that may not align with current sentiment.

Zai Lab's recent history of EPS surprises suggests potential for better-than-expected performance.

Key Risk

If clinical trial results are announced that exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to manage costs while advancing its drug development pipeline.

Bull Confirmed If

A narrower EPS loss than the previous quarter could signal improved operational efficiency.

Bear Confirmed If

A wider EPS loss or delays in clinical trials would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±11.2%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±7.5% while ZLAB has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

58.7%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zai Lab beats expectations, history suggests the stock could rise by an average of 3.68%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 1.10%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any commentary on cost management strategies and future financial outlook.
3Details on partnerships or collaborations that could enhance drug development.
4Insights into market opportunities for Zai Lab's products.
5Management's perspective on competitive positioning in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

CNAReported

CNA Financial Corporation

RecapView

May4

LReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and support future investments.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+0.83%

Avg Stock Reaction

-3.30%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Zai Lab's earnings report, especially given the company's recent performance. However, the lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Zai Lab can demonstrate better-than-expected progress in its clinical trials or report a narrower EPS loss, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company reports a larger-than-expected loss or delays in its drug development timelines, it could lead to a negative reaction from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Zai Lab's clinical trials?

Updates on clinical trials can significantly impact the company's future prospects and investor sentiment.

How does Zai Lab plan to manage its operating expenses moving forward?

Understanding expense management is crucial for assessing the company's path to profitability and financial stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of Zai Lab's ongoing clinical trials, which could yield positive results sooner than anticipated.

Supporting Evidence

The options market is pricing a significant move, indicating expectations of volatility that may not align with current sentiment.

Zai Lab's recent history of EPS surprises suggests potential for better-than-expected performance.

Key Risk

If clinical trial results are announced that exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to manage costs while advancing its drug development pipeline.

Bull Confirmed If

A narrower EPS loss than the previous quarter could signal improved operational efficiency.

Bear Confirmed If

A wider EPS loss or delays in clinical trials would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±11.2%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±7.5% while ZLAB has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

58.7%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zai Lab beats expectations, history suggests the stock could rise by an average of 3.68%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 1.10%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any commentary on cost management strategies and future financial outlook.
3Details on partnerships or collaborations that could enhance drug development.
4Insights into market opportunities for Zai Lab's products.
5Management's perspective on competitive positioning in the biotechnology sector.